On April 6, 2026, Dr. Minetta Liu, from Georgetown Lombardi Comprehensive Cancer Center, emphasized that triple-negative breast cancer (TNBC) is treatable if caught early. Despite TNBC's aggressive nature and higher recurrence rates, particularly within the first three to five years post-treatment, early detection is crucial for improving patient outcomes and survival rates. The research underscores the importance of prompt diagnosis to effectively manage this form of breast cancer.
TNBC lacks estrogen, progesterone, and HER2 receptors, making hormone therapy and HER2-targeted drugs ineffective, thus relying on chemotherapy as the primary treatment. Dr. Liu also noted that PARP inhibitors are effective for patients with BRCA mutations. The article highlighted sacituzumab govitecan-hziy (Trodelvy), a recently FDA-approved drug, as a new treatment option for advanced TNBC. TNBC accounts for 10-15% of all breast cancers, is more prevalent in women under 40 and Black women, and is associated with higher rates of recurrence and metastasis.
The article stresses that early diagnosis of TNBC often allows for successful treatment using surgery, chemotherapy, and radiation, leading to a good prognosis. Continued research at institutions like Georgetown Lombardi aims to develop more targeted therapies and diagnostic tools to further improve outcomes for TNBC patients. While the first three to five years are critical for recurrence, patients who remain cancer-free beyond this period often achieve a similar long-term prognosis to those with other breast cancer types.
